Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease

Mustafa Ceylan ¹ , Murat Gültekin ² , Nazlı Durmaz Çelik ³ , Bedia Samanci ⁴ , Gül Yalçin Çakmakli ⁵ , Rezzak Yilmaz ⁶

Author Affiliation(s)

Department of Neurology, Atatürk University Faculty of Medicine, Movement Disorders and Neuromodulation Center, Erzurum, Turkey

Department of Neurology, Erciyes University Faculty of Medicine, Kayseri, Turkey

Department of Neurology, Osmangazi University Faculty of Medicine, Eskişehir, Turkey

Department of Neurology, İstanbul University İstanbul Faculty of Medicine, Behavioral Neurology and Movement Disorders Unit, İstanbul, Turkey

Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Department of Neurology, Ankara University Faculty of Medicine, Ankara, Turkey

Eurasian J Med 2022; 54: Supplement S71-S76

DOI: 10.5152/eurasianjmed.2022.22134

Keywords : Parkinson’s disease, apomorphine, motor symptoms, non-motor symptoms

Read: 1138 Downloads: 471 Published: 01 December 2022

Volume 54, Issue 1, December 2022

The intermittent subcutaneous injection of apomorphine is highly effective in the management of motor and non-motor symptoms of Parkinson’s disease. Although it has been shown that apomorphine injection can be safely used in selected cases at all stages of the disease, there is no consensus regarding intermittent administration strategies. This review aimed to discuss the indications for intermittent subcutaneous apomorphine use in clinical practice, possible side effects and their management, and contraindicated cases in light of the literature and to present practical recommendations for clinical practice.

Cite this article as: Ceylan M, Gültekin M, Durmaz Çelik N, Samanci B, Yalçin Çakmakli G, Yilmaz R. The role and use of intermittent subcutaneous injections of apomorphine in Parkinson’s disease. Eurasian J Med., 2022;54(Suppl. 1):S71-S76.

Files

Full Text PDF